Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07638982
PHASE1
Axatilimab + CAR-T for High-Risk Lymphoma
Sponsor: Northside Hospital, Inc.
View on ClinicalTrials.gov
Summary
Axatilimab + CAR-T in High-Risk Lymphoma
Official title: An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)
Key Details
Gender
All
Age Range
8 Years - Any
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2026-12-31
Completion Date
2029-12-31
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
DRUG
Axatilimab
Dose Level -1: 0.1mg/kg Dose Level +1: 0.3mg/kg Dose Level +2: 1mg/kg Dose Level +3: 3mg/kg
Locations (1)
Northside Hospital
Atlanta, Georgia, United States